This Is MS Multiple Sclerosis Community: Knowledge & Support

Neurologists twice as aware of oral MS drug Cladribine than oral FTY-720



Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed neurologists have low awareness of Novartis/Mitsubishi Tanabe's FTY-720 (Gilenia) among the surveyed oral emerging therapies for the treatment of multiple sclerosis (MS).

According to the new report, Brand Perception Series: Physician Segmentation in Multiple Sclerosis, just over one-third of surveyed physicians have heard of FTY-720 (Gilenia) compared with three-quarters of surveyed physicians who are aware of Merck Serono/EMD Serono's oral cladribine and half of surveyed physicians who are aware of Teva/Active Biotech's laquinimod....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1629

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis